Clinical Trials on Chronic Graft-versus-host Disease in New Zealand
Total 7500 results
-
University of RochesterWithdrawnActive Chronic Graft Versus Host DiseaseUnited States
-
M.D. Anderson Cancer CenterCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingGraft-Versus-Host Disease | GVHD | UndefinedUnited States
-
University of RochesterTerminatedChronic Graft Versus Host DiseaseUnited States
-
Yale UniversityTerminatedGraft Versus Host DiseaseUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedGraft Versus Host DiseaseUnited States, Canada, Australia, Switzerland, Puerto Rico, New Zealand
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Graft Versus Host DiseaseUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedGraft Versus Host DiseaseUnited States
-
MallinckrodtParexelCompletedChronic Graft Versus Host DiseaseUnited States, France, Germany, United Kingdom, Spain, Italy, Austria, Hungary
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompleted
-
MallinckrodtCompletedGraft-versus-Host DiseaseUnited States, Australia, France, Italy, Austria, Germany, Portugal, Slovakia, Spain, Switzerland, Turkey, United Kingdom
-
ActelionTerminatedChronic Graft Versus Host DiseaseUnited States
-
Pharmacyclics LLC.Janssen Research & Development, LLCCompletedChronic Graft Versus Host DiseaseUnited States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan
-
Gilead SciencesTerminatedChronic Graft Versus Host DiseaseSpain, Korea, Republic of, United States, Germany, Canada, France, United Kingdom
-
Ann & Robert H Lurie Children's Hospital of ChicagoAstex Pharmaceuticals, Inc.CompletedGraft vs Host DiseaseUnited States
-
Dartmouth-Hitchcock Medical CenterTerminatedChronic Graft-versus-host-diseaseUnited States
-
Incyte CorporationCompletedGraft-versus-host Disease (GVHD)United States, Spain, Belgium, France, Italy, Korea, Republic of, Finland, United Kingdom, Germany, Israel, Switzerland, Austria, Australia, Czechia, Greece, New Zealand, Poland, Portugal, Taiwan
-
McMaster UniversitySanofi; Ozmosis Research Inc.; Cell Therapy Transplant CanadaRecruitingAcute Leukemia | Myelodysplasia | Chronic Graft-versus-host-diseaseCanada, Australia
-
Memorial Sloan Kettering Cancer CenterIncyte Corporation; Hackensack Meridian HealthCompletedNon-sclerotic Cutaneous Chronic Graft-versus-host DiseaseUnited States
-
NYU Langone HealthRecruiting
-
NYU Langone HealthActive, not recruitingGraft-versus-host DiseaseUnited States
-
AmgenCompletedChronic Graft-versus-Host Disease (cGVHD)Australia
-
Alexion PharmaceuticalsTerminatedAcute Graft-Versus-Host Disease | GIGVHDUnited States, France
-
Columbia UniversityIncyte CorporationTerminatedGraft Vs Host Disease | Steroid Refractory GVHDUnited States
-
Genentech, Inc.TerminatedAcute Graft-versus-host DiseaseUnited States, Canada
-
Regimmune CorporationCompletedGraft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Prevention of aGVHDUnited States
-
Genentech, Inc.Completed
-
Jazz PharmaceuticalsCompletedAcute-graft-versus-host Disease | Graft-versus-host DiseaseUnited States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
Incyte CorporationCompletedGraft-versus-host Disease (GVHD)United States
-
Mesoblast, Inc.No longer availableGraft-Versus-Host DiseaseUnited States
-
Mesoblast, Inc.Quintiles, Inc.CompletedGrade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host DiseaseUnited States
-
Incyte CorporationCompletedGraft-versus-host Disease (GVHD)United States
-
Northwell HealthWithdrawnAcute GVH DiseaseUnited States
-
Incyte CorporationApproved for marketingGraft-versus-host Disease (GVHD)United States
-
Cynata Therapeutics LimitedCompletedGraft vs Host DiseaseAustralia, United Kingdom
-
MallinckrodtPRA Health SciencesTerminatedAcute Graft-versus-Host DiseaseUnited States, Canada, Germany, United Kingdom, Australia, Austria, Belgium, Italy, France, Netherlands, Switzerland
-
Fred Hutchinson Cancer CenterAstraZenecaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Recurrent Moderate-Severe Chronic Graft Versus Host DiseaseUnited States
-
Syndax PharmaceuticalsActive, not recruitingChronic Graft-versus-host-diseaseKorea, Republic of, United States, Spain, Taiwan, France, Singapore, Belgium, Germany, Italy, Canada, Israel, Australia, United Kingdom, Greece, Poland, Portugal
-
Incyte CorporationTerminatedAcute Graft-versus-host DiseaseUnited States, Spain, France, Italy, United Kingdom, Germany
-
John LevineBiogenCompletedAcute Graft Versus Host DiseaseUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedGraft Versus Host DiseaseUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedGraft Versus Host DiseaseUnited States
-
EquilliumBiocon LimitedRecruitingGraft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHDUnited States, Korea, Republic of, Israel, Spain, Germany, Belgium, Italy, Australia, France, Canada, Portugal
-
Memorial Sloan Kettering Cancer CenterMillennium: The Takeda Oncology CompanyCompletedMyeloid Hematologic Malignancy | Lymphoid Hematologic MalignancyUnited States
-
XenikosNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsTerminatedSteroid-Refractory Acute Graft Versus Host DiseaseUnited States
-
Incyte CorporationTerminatedChronic Graft-versus-host DiseaseUnited States, Spain, France, Canada, Israel, United Kingdom, Germany, Italy, Denmark, Sweden, Finland, Belgium, Poland, Greece, Austria, Switzerland
-
Kadmon, a Sanofi CompanyTerminatedEfficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyChronic Graft-versus-host-diseaseUnited States
-
Mesoblast, Inc.CompletedGraft Versus Host DiseaseUnited States, Italy, Australia, Canada, Switzerland, United Kingdom
-
EquilliumBiocon LimitedRecruitingGVHD | GVHD, Acute | aGVHD | Acute-graft-versus-host DiseaseUnited States